Endocrine Abstracts

Background: Stimulated Thyroglobulin levels measured at the time of remnant ablation (Htg-A) and BRAFV600E mutation were shown to have prognostic value in predicting persistent disease in DTC. The aim of this study was to evaluate the prognostic role of Htg-A combined with BRAFV600E status in association with revised American Thyroid Association (ATA) risk stratification.Patients and methods: 620 patients treated for a DTC were included in this study wit...

Introduction: Differentiated thyroid cancers (DTCs) carrying BRAF and TERT mutations are associated with high-risk clinicopathological features and poor prognosis. However, there are currently no studies comparing BRAF-TERT tumors to other double mutated DTCs.Aim: To verify whether BRAF-TERT mutated DTCs differ from other double mutated DTCs in terms of clinicopathological characteristics and outcome.Materials and Methods: 168 DTCs...

Introduction: There is no clear indication for radioiodine treatment (RAI) in patients affected by differentiated thyroid cancer (DTC) in Stage I and ATA intermediate risk, according to American Thyroid Association (ATA) guidelines.Purpose: Our aim is to evaluate whether integration of BRAF status and thyroglobulin TSH-stimulated at the time of RAI (A-HTg) could further improve accuracy of stratification, and therefore therapeutic management, in DTC pati...

Introduction: Although 18F-FDG-PET has found wide application in the management of radio-refractory differentiated thyroid cancers (RAI-R-DTCs), alternative radiotracers, including 68Ga-PSMA have been recently evaluated. Prostate-specific membrane antigen (PSMA) is in fact overexpressed in the microvasculature of several solid malignancies including thyroid cancers.Aim: To compare the diagnostic performance between 68Ga-P...

BackgroundMost Differentiated Thyroid Cancer (DTC) cases typically show indolent biological behavior and a low mortality rate. Various prognostic systems are used to assess disease recurrence risk, to tailor treatment and follow-up strategies. The initial Risk Stratification System (RSS) and dynamic Response to Therapy Re-stratification (RTR) system, recommended by the 2015 American Thyroid Association (ATA) Guidelines, are the most employed. Still, they...